Qiagen

Qiagen N.V. is a leading global provider of sample to insight solutions that transform biological samples into molecular insights. The company specializes in sample technology consumables and instruments, serving the molecular diagnostics and life sciences sectors worldwide.

Products and Services

• Nucleic acid stabilization and purification kits
• Instruments for nucleic acid purification and quality control
• Assays for oncology, infectious diseases, and genetic testing

Growth Outlook

• Revenue of $492.3 million in Q1 2026, showing strong demand
• Trailing twelve months (TTM) revenue growth of 5.5% year-over-year
• Expansion into emerging markets expected to drive future growth

Financial Highlights

• Net income of $68.0 million in Q1 2026, reflecting solid profitability
• Operating income margin of 23.7% in Q1 2026, indicating operational efficiency
• Dividend yield of 6.83% TTM, appealing for income-focused investors

Qiagen N.V. has established itself as a key player in the healthcare sector, particularly in diagnostics and research. The company's diverse product offerings cater to a wide range of applications, from infectious disease testing to oncology. Recent financial performance highlights a robust revenue stream and profitability, with a notable operating income margin that underscores effective cost management. The company's commitment to innovation and expansion into new markets positions it well for sustained growth in the future. With a strong dividend yield, Qiagen N.V. may attract investors looking for both growth and income opportunities.